KRAS Tests Market Size by Segments, Share, Regulatory, Reimbursement, and Forecast to 2033
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
KRAS Tests Market Report Overview
The KRAS tests market size was $80.4 million in 2023. The market is expected to grow at a CAGR of more than 6% during 2023-2033. Kirsten rat sarcoma virus (KRAS) gene tests are carried out to detect gene mutations in patient tissue samples. The outcome of these tests may guide therapies to treat various cancers including colorectal cancer, certain lung cancers, and some leukemias.
KRAS Tests Market Outlook, 2023-2033 ($ Million)
Buy the Full Report for More Insights into the KRAS Tests Market Forecast
The KRAS Tests market research report has been created to understand market behavior, which will help identify quantitative market trends in the In Vitro Diagnostics therapeutic area. It discusses in detail the impact of COVID-19 on the KRAS tests market for the year 2020 and beyond. The report has extensively covered pipeline products and technologies, which will help in identifying companies with the most robust pipeline. This, in turn, will assist in predictive analysis for designing your in-licensing and out-licensing strategies.
Market Size (2023) | $80.4 million |
CAGR (2023-2033) | >6% |
Forecast Period | 2023-2033 |
Historical Period | 2015-2022 |
Key Segments | · KRAS Nucleic Acid Amplification Tests (NAATs)
· KRAS Other Tests · KRAS Sanger Sequencing Tests |
Key Regions | · North America
· Europe · Asia Pacific · South America · Middle East and Africa |
Leading Companies | · Roche Diagnostics International Ltd + Foundation Medicine Inc
· Qiagen NV · Agilent Technologies Inc · Illumina Inc · Thermo Fisher Scientific Inc |
Enquire & Decide | Discover the perfect solution for your business needs. Enquire now and let us help you make an informed decision before making a purchase. |
KRAS Tests Market Dynamics
Kirsten rat sarcoma (KRAS) is a downstream signaling molecule in the EGFR cellular pathway with roles in cell growth and proliferation. It is commonly mutated in both CRC and NSCLC. GlobalData predicts that the market for KRAS tests will grow across all regions during the forecast period. This growth is driven by several factors including increased incidence of colorectal and lung cancer, greater disease awareness, improved accessibility to anti-EGFR therapies in emerging economies, technological advancements such as next-generation sequencing (NGS), and the ability to utilize circulating tumor DNA (ctDNA) for mutation detection.
KRAS Tests Market Segments
The key segments in the KRAS tests market are KRAS Nucleic Acid Amplification Tests (NAATs), KRAS other tests, and KRAS Sanger Sequencing Tests. KRAS Nucleic Acid Amplification Tests (NAATs) led the KRAS tests market in 2023. A KRAS nucleic acid amplification test (NAAT) involves the amplification of specific nucleic acid sequences related to the target KRAS gene or mutation.
KRAS Tests Market Analysis by Segments, 2023 (%)
Buy the Full Report for More Segment Insights into the KRAS Tests Market
KRAS Tests Market Segmentation by Regions
The key regions in the KRAS tests market are North America, Europe, Asia Pacific, South America, and the Middle East and Africa. In 2023, Europe dominated the KRAS tests market. NGS is routinely being used to identify KRAS mutations throughout Europe, especially in CRC. However, there are large regional differences in the prevalence of NGS use. For instance, pyrosequencing is widely used in the U.K. but is less common in countries such as the Netherlands.
KRAS Tests Market Analysis by Regions, 2023 (%)
Buy the Full Report for More Regional Insights into the KRAS Tests Market
KRAS Tests Market - Competitive Landscape
A few of the leading companies in the KRAS tests market are:
- Roche Diagnostics International Ltd + Foundation Medicine Inc
- Qiagen NV
- Agilent Technologies Inc
- Illumina Inc
- Thermo Fisher Scientific Inc
Qiagen NV dominated the market in 2023.
KRAS Tests Market Analysis by Companies, 2023 (%)
Buy the Full Report for More Company Insights into the KRAS Tests Market
Segments Covered in the Report
KRAS Tests Segments Outlook (Value, $ Million, 2015-2033)
- KRAS Nucleic Acid Amplification Tests (NAATs)
- KRAS Other Tests
- KRAS Sanger Sequencing Tests
KRAS Tests Regional Outlook (Value, $ Million, 2015-2033)
- North America
- Europe
- Asia Pacific
- South America
- Middle East & Africa
Key Inclusions
Currently marketed KRAS Tests and evolving competitive landscape:
- Insightful review of the key industry trends.
- Annualized total KRAS Tests market revenue by segment and market outlooks from 2015-2033.
- Market-level data on units, average selling prices, and market values.
Global, Regional, and Country level market specific insights:
- Qualitative market-specific information is available with global trends further broken down into regional trends. In addition, GlobalData analysts provide unique country-specific insights on the market.
- SWOT analysis for the KRAS Tests market.
- Competitive dynamics insights and trends provided for the KRAS Tests market.
Drive the understanding of the market by getting the veritable big picture including an overview of the healthcare system. In addition, the Market Access segment allows you to delve deeper into market dynamics with information on reimbursement policies and the regulatory landscape.
- Country-specific overview of the healthcare system.
- Country-specific reimbursement policies.
- Country-specific medtech regulatory landscape.
Robust methodologies and sources enable the model to provide an extensive and accurate overview of the market. Demand and supply-side primary sources are integrated within the syndicated models, including Key Opinion Leaders. In addition, real-world data sources are leveraged to determine market trends; these include government procedure databases, hospital purchasing databases, and proprietary online databases.
Companies covered: F. Hoffmann-La Roche Ltd, Qiagen NV, Agilent Technologies Inc, Illumina Inc, Thermo Fisher Scientific Inc, Abbott Laboratories, NimaGen BV, Mesa Laboratories Inc, New England Biolabs Inc, Amoy Diagnostics Co Ltd, HLB PanaGene Co Ltd, EntroGen, Inc, Sysmex Corp, Biocartis Group NV, and others.
Countries covered: United States, United Kingdom, Germany, France, Italy, Spain, Brazil, China, India, Russia, Japan, Australia, Canada, Mexico, South Korea, Denmark, Ireland, Netherlands, New Zealand, South Africa, Sweden, Switzerland, Austria, Belgium, Finland, Israel, Norway, Poland, Portugal, Taiwan, Czech Republic, Greece, Hungary, Turkey, Egypt, Saudi Arabia, United Arab Emirates, Argentina, and Chile.
Scope
This report provides:
- Insightful review of the key industry trends.
- Annualized total KRAS Tests market revenue by segment and market outlooks.
- Market-level data on units, average selling prices, and market values.
- Global, regional, and country-level market-specific insights including qualitative market-specific information with global trends further broken down into regional trends. In addition, GlobalData analysts provide unique country-specific insights on the market.
- SWOT analysis for the KRAS Tests market.
- Competitive dynamics insights and trends provided for the KRAS Tests market.
- Country-specific overview of the healthcare system.
- Country-specific reimbursement policies.
- Country-specific medtech regulatory landscape.
Reasons to Buy
The model will enable you to:
- Understand the impact of COVID-19 on the KRAS Tests market.
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the KRAS Tests market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the KRAS Tests market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the company share of market leaders.
- Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain a competitive advantage.
- Track device sales in the global and country-specific KRAS Tests market from 2015-2033.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
Qiagen NV
Agilent Technologies Inc
Illumina Inc
Thermo Fisher Scientific Inc
Abbott Laboratories
NimaGen BV
Mesa Laboratories Inc
New England Biolabs Inc
Amoy Diagnostics Co Ltd
HLB PanaGene Co Ltd
EntroGen, Inc
Sysmex Corp
Biocartis Group NV
Frequently asked questions
-
What was the KRAS tests market size in 2023?
The KRAS tests market size was $80.4 million in 2023.
-
What will the KRAS tests market growth rate be during the forecast period?
The KRAS tests market is expected to grow at a CAGR of more than 6% during 2023-2033.
-
Which region dominated the KRAS tests market in 2023?
Europe dominated the overall KRAS tests market in 2023.
-
Which segment led the KRAS tests market in 2023?
KRAS Nucleic Acid Amplification Tests (NAATs) led the KRAS tests market in 2023.
-
Which are the leading companies in the KRAS tests market?
A few of the leading companies in the KRAS tests market are Roche Diagnostics International Ltd + Foundation Medicine Inc, Qiagen NV, Agilent Technologies Inc, Illumina Inc, and Thermo Fisher Scientific Inc., among others.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.